We are live on ! Find out more

MAZE

Maze Therapeutics

MAZE

Market cap $1.34B

24.11 USD

-0.12

0.5%

At close Updated Sep 16, 2:27 PM EDT

1 day

-0.5%

5 days

-0.62%

1 month

-13.74%

3 months

1.05%

6 months

-52.97%

Year to date

-39.38%

1 year

2.77%

5 years

51.16%

10 years

51.16%

About: Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Employees: 141

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 62.5%

Negative 12.5%

The Motley Fool

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Chief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026. The transaction involved shares equal to 100% of the insider's directly held common stock before the filing.

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m.

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces competition from Vertex's inaxaplin; pivotal trials are planned for 1H 2027.

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Maze Therapeutics Announces Appointments to Its Board of Directors

Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze's Board of Directors, adding to the Company's deep bench of clinical and industry experience

Maze Therapeutics Announces Appointments to Its Board of Directors

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and marketable securities supports expected runway into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the second quarter ended June 30, 2026, highlighting recent progress and business updates.

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Zacks Investment Research

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

The Motley Fool

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

CEO Jason Coloma sold 27,858 shares for a total value of approximately $725,000 across June 22 and June 23, 2026. This transaction involved Coloma's indirect holdings and reduced indirect ownership from 372,867 to 345,009 shares.

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences:

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

See News Rankings

Price charts implemented using Lightweight Charts™